Zubu Client Sentiment Nifty50 Report & Market Recap (Dec-03-2021)
Zubu Client Sentiment Nifty50 Report:
It is a Post Market Analysis, by which one can understand Retail trader’s sentiment and discover who was going long and short, the percentage change over time, and whether market signals are bullish or bearish
Nifty50 retail trader data shows 51.67% of traders are net-long, while the number of traders net-short was 48.33%. FII’s unwinded huge longs -20780 & created huge shorts 6108, while retailers created huge longs 21693 & unwinded huge shorts -16031.
Nifty50: 17,196 ▼-204.9 (-1.1%) Sensex: 57,696 ▼-764.8 (-1.3%)
After a gap-up opening, the markets witnessed intense selling pressure Of the Nifty50 pack, 38 stocks declined. Among the Nifty sectoral indices, Financial Services (-1.1%) and Oil and Gas (-1.0%) were the top losers. Whereas, Media (+1.7%) was the only gainer.
Top gainers Today’s change
UPL ▲ 2.1%
BPCL ▲ 1.8%
IOC ▲ 1.4%
Top losers Today’s change
Power Grid ▼ 4.0%
Reliance ▼ 2.8%
Kotak Bank ▼ 2.2%
KEC jumps on new orders
The infrastructure company bagged new orders worth ₹1,065 crore across its various business verticals such as transmission and distribution , railways, etc.
With the announcement of this order, their year to date order intake now stands at nearly ₹11,000 crore, which is 2.5 times higher than the last year. The company is currently executing infrastructure projects in 30 plus countries. Its stock rose about 4% intraday but erased all gains amidst weak market.
L&T to tap green hydrogen market
The engineering giant will partner with a renewable energy company, ReNew for green hydrogen projects in India.
Meanwhile, L&T also entered into a distribution agreement with Germany-based Kemroc. Under the agreement it will facilitate distribution and promotion of Kemroc products in the Indian markets. Kemroc is a global manufacturer of attachments for excavators, backhoe loaders and chain cutters. Shares of L&T were up 3% intraday.
Unichem surges on USFDA nod
Shares of the pharmaceutical company surged today after it received approval for its Aripiprazole tablets from the USFDA. Aripiprazole tablets are used to treat schizophrenia and irritability associated with Autism.
The new product will be commercialized from the company’s Ghaziabad plant. Meanwhile, the company is facing pricing pressures in its key export market – the US – which impacted the profitability in the first half of the current fiscal.
After falling for two consecutive weeks, the markets gained 1% this week. The bounce-back was driven by the IT stocks, without much help from banks or heavy weight Reliance Industries. The services PMI showed expansion of activities, which is a boost for investor sentiments. Meanwhile, companies across various sectors are reportedly passing higher input costs to the customers. This could fuel the risk of higher inflation. Next week, the RBI will announce its interest rate decision. The challenge for the central bank would be to strike a balance between its pro-growth stance (amid virus uncertainty) and controlling the rising inflation risk.